241 related articles for article (PubMed ID: 36157504)
1. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML).
Cao Z; Shu Y; Wang J; Wang C; Feng T; Yang L; Shao J; Zou L
Genes Dis; 2022 Nov; 9(6):1466-1477. PubMed ID: 36157504
[TBL] [Abstract][Full Text] [Related]
2. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Fang F; Lu J; Sang X; Tao YF; Wang JW; Zhang ZM; Zhang YP; Li XL; Xie Y; Wu SY; Chu XR; Li G; Wu D; Chen YL; Yu JJ; Jia SQ; Feng CX; Tian YY; Li ZH; Ling J; Hu SY; Pan J
J Exp Clin Cancer Res; 2022 Jul; 41(1):225. PubMed ID: 35842703
[TBL] [Abstract][Full Text] [Related]
3. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
4. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
[TBL] [Abstract][Full Text] [Related]
5. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.
Jia Y; Chng WJ; Zhou J
J Hematol Oncol; 2019 Jul; 12(1):77. PubMed ID: 31311566
[TBL] [Abstract][Full Text] [Related]
6. [Understanding of molecular pathogenesis of T-cell leukemia by super-enhancer profiling].
Sanda T
Rinsho Ketsueki; 2018; 59(7):899-908. PubMed ID: 30078801
[TBL] [Abstract][Full Text] [Related]
7. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
[TBL] [Abstract][Full Text] [Related]
8. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
9. Super-Enhancers Dysregulations in Hematological Malignancies.
Belloucif Y; Lobry C
Cells; 2022 Jan; 11(2):. PubMed ID: 35053311
[TBL] [Abstract][Full Text] [Related]
10. The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino S; Suzuki HI
Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
[TBL] [Abstract][Full Text] [Related]
11. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
12. An oncogenic enhancer encodes selective selenium dependency in AML.
Eagle K; Jiang Y; Shi X; Li M; Obholzer NP; Hu T; Perez MW; Koren JV; Kitano A; Yi JS; Lin CY; Nakada D
Cell Stem Cell; 2022 Mar; 29(3):386-399.e7. PubMed ID: 35108519
[TBL] [Abstract][Full Text] [Related]
13. Targeting super-enhancer activity for colorectal cancer therapy.
Voutsadakis IA
Am J Transl Res; 2024; 16(3):700-719. PubMed ID: 38586095
[TBL] [Abstract][Full Text] [Related]
14. Runt-Related Transcription Factor 3 Promotes Acute Myeloid Leukemia Progression.
Zhang W; Ma Q; Long B; Sun Z; Liu L; Lin D; Zhao M
Front Oncol; 2021; 11():725336. PubMed ID: 34722267
[TBL] [Abstract][Full Text] [Related]
15. Targeting Super-Enhancers as a Therapeutic Strategy for Cancer Treatment.
He Y; Long W; Liu Q
Front Pharmacol; 2019; 10():361. PubMed ID: 31105558
[TBL] [Abstract][Full Text] [Related]
16. NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
Di Benedetto C; Oh J; Choudhery Z; Shi W; Valdes G; Betancur P
BMC Cancer; 2022 Oct; 22(1):1056. PubMed ID: 36224576
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
Reyes-Garau D; Ribeiro ML; Roué G
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
[TBL] [Abstract][Full Text] [Related]
18. Super-enhancers in cancer.
Thandapani P
Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
[TBL] [Abstract][Full Text] [Related]
19. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
20. DEEPSEN: a convolutional neural network based method for super-enhancer prediction.
Bu H; Hao J; Gan Y; Zhou S; Guan J
BMC Bioinformatics; 2019 Dec; 20(Suppl 15):598. PubMed ID: 31874597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
